Human 3 with Brom and Sam30 Jul 2025

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP

2025 has been the start of a bull period for psychedelic medicine.

Psychedelic Biotechs like GH Research, Compass Pathways and Lykos Therapeutics are releasing impressive, late stage clinical trial data

Capital is following the data: Cybin just raised $500M and Johnson and Johnson's Ketamine-inspired antidepressant Spravato broke $1B+ / year of topline.

A new administration seems surprisingly interested in accelerating the FDA approval of psychedelics as treatments for mental health disorders

Learn how top VCs and LPs are mapping and allocating to this exciting space in this special event designed for family offices and HNWIs.

You will learn:

The contrasting approaches that biotech and pharma are taking to commercialize psychedelic medicine

Where we see the highest-leverage points for investing

Lessons from past failures

And of course there will be plenty of time for interaction and Q&A

This event is run by Brom Rector and Sam Tabone of XEIA, a venture capital fund that invests in "Human 3 - the next epoch of human health, wellbeing and performance". As part of their Human 3 thesis, they have invested in 8 psychedelic medicine companies from pre-seed to pre-IPO.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(32)

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Aug 20251h 24min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Jul 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Jul 20251h 33min

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Jul 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Jul 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Jul 20251h

The BioIndustrial Revolution: Why Peter Thiel and Chris Sacca backed Arye's Biomanufacturing Startup

Arye Lipman is the cofounder of Biosphere, a startup that recently raised millions of dollars from Peter Thiel's Founders Fund and Chris Sacca's Lower Carbon Capital to Unleash Industrial Biomanufactu...

30 Jun 20251h 20min